metabol
arbidol
human
studi
use
liquid
chromatographyelectrospray
ioniz
esi
ion
trap
mass
spectrometri
itm
oral
dose
arbidol
total
metabolit
identifi
includ
glucuronid
arbidol
glucuronid
sulfinylarbidol
major
metabolit
arbidol
metabolit
common
fragment
pattern
result
homolyt
bond
cleavag
cleavag
form
oddelectron
ion
loss
radic
arbidol
fragment
sequenc
first
lose
dimethylamin
da
follow
loss
acetaldehyd
da
phenylthio
radic
da
fragment
sequenc
also
observ
ndemethylarbidol
sulfonylarbidol
ndemethylsulfonylarbidol
howev
sulfinylarbidol
ndemethylsulfinylarbidol
fragment
sequenc
revers
phenylsulfini
radic
identifi
observ
neutral
loss
da
da
glucuron
acid
ms
spectra
sulfat
glucuronid
conjug
sulfinylarbidol
ndemethylsulfinylarbidol
unusu
fragment
pattern
phenylsulfinyl
radic
da
lost
loss
group
da
glucuron
acid
da
occur
wang
et
al
retent
time
min
c
h
c
valu
mz
respect
result
mz
plu
da
ms
spectrum
mz
arbidol
antivir
activ
chemic
entiti
creat
chemic
drug
center
russian
research
institut
pharmaceut
chemistri
togeth
institut
medic
radiolog
earli
report
show
arbidol
inhibit
influenza
virusinduc
membran
fusion
may
capac
induc
serum
interferon
russia
arbidol
use
treatment
influenza
sever
year
recent
studi
show
arbidol
exhibit
inhibitori
activ
human
virus
respiratori
syncyti
viru
parainfluenza
viru
rhinoviru
hepat
b
viru
bird
virus
avian
coronaviru
influenza
viru
also
shown
sensit
arbidol
arbidol
consid
broadspectrum
antivir
compound
wide
use
treatment
influenza
kind
respiratori
infect
fair
safeti
efficaci
arbidol
becom
wide
use
strong
demand
better
understand
parent
compound
well
metabol
pathway
human
physiolog
mechan
arbidol
report
activ
phagocyt
activ
macrophag
stimul
form
cellular
humor
immun
pharmacokinet
studi
anim
shown
arbidol
absorb
distribut
quickli
tissu
organ
oral
administr
quantit
determin
arbidol
human
plasma
also
report
recent
year
metabol
behavior
arbidol
scarc
studi
literatur
search
result
singl
articl
publish
metabolit
arbidol
rat
urin
identifi
use
thinlay
chromatographi
tlclc
coupl
mass
spectrometri
human
metabol
studi
arbidol
report
far
articl
report
metabolit
arbidol
identifi
human
urin
use
high
perform
liquid
chromatographi
hplc
coupl
ion
trap
mass
spectromet
itm
liquid
chromatographi
coupl
mass
spectrometri
lcm
wide
accept
ideal
analyt
techniqu
metabol
character
tradit
approach
metabolit
identif
use
tripl
quadrupol
mass
spectrometri
initi
fullscan
screen
potenti
metabolit
identifi
confirm
along
possibl
site
biotransform
identifi
perform
precursor
ion
scan
product
scan
well
neutral
loss
scan
disadvantag
approach
singl
msm
experi
usual
insuffici
local
site
biotransform
itm
attract
choic
sinc
use
narrow
site
biotransform
studi
fragment
pattern
ms
n
experi
work
sensit
specif
lcelectrospray
ioniz
esi
itm
method
develop
identif
arbidol
metabolit
human
urin
meanwhil
fragment
sequenc
arbidol
metabolit
investig
collisioninduc
dissoci
cid
pathway
deduc
detail
even
though
compound
structur
close
relat
analog
import
major
fragment
ion
also
posit
confirm
exact
mass
measur
use
hplcqtof
ms
quadrupoletimeofflight
mass
spectromet
arbidol
refer
puriti
provid
courtesi
professor
ping
gong
shenyang
pharmaceut
univers
liaon
china
hplc
grade
methanol
purchas
sigma
chemic
co
st
loui
mo
usa
ammonium
acet
hplc
grade
purchas
e
merck
darmstadt
germani
distil
water
obtain
inhous
millipor
milliq
water
purif
system
millipor
bedford
usa
sulfinylarbidol
sulfonylarbidol
puriti
base
hplcm
analysi
synthes
laboratori
structur
identifi
posit
esim
n
h
nmr
c
nmr
stock
solut
arbidol
prepar
methanol
hplcitm
experi
carri
agil
lcmsd
trap
xct
ultra
agil
technolog
waldbronn
germani
agil
hplc
equip
reversedphas
column
ultim
xbc
mm
mm
id
welch
materi
usa
protect
mm
mm
id
secur
guard
c
guard
column
phenomenex
torranc
ca
usa
mobil
phase
gradient
mixtur
methanol
b
ammonium
acet
program
follow
initi
maintain
min
increas
min
maintain
min
increas
min
maintain
min
final
decreas
min
maintain
min
flow
rate
mlmin
inject
volum
mass
spectromet
msd
equip
esi
sourc
ioniz
mode
posit
interfac
msd
paramet
follow
nebul
pressur
psi
n
dri
ga
mlmin
n
dri
ga
temperatur
spray
capillari
voltag
v
skimmer
voltag
v
ion
transfer
capillari
exit
v
scan
rang
mz
spectra
averag
target
dwell
time
ms
ms
n
spectra
fragment
amplitud
vari
v
paramet
includ
potenti
octapol
offset
tube
len
offset
also
optim
maximum
abund
ion
interest
automat
tune
procedur
instrument
ms
n
product
spectra
produc
cid
molecular
ion
c
h
c
analyt
respect
hplc
retent
time
data
acquisit
perform
fullscan
lcm
high
mass
resolut
experi
carri
ultima
global
tandem
qtof
ms
water
corpor
manchest
uk
esi
oper
use
nitrogen
desolv
nebul
ga
temperatur
spray
capillari
cone
voltag
set
v
respect
cone
block
heat
set
potenti
v
cid
experi
argon
use
collis
ga
collis
energi
set
v
instrument
control
data
acquisit
process
perform
masslynx
data
system
version
arbidol
capsul
shijiazhuang
pharmaceut
co
ltd
heibei
china
use
work
purchas
regular
pharmaci
arbidol
overthecount
drug
china
arbidol
capsul
given
two
nonsmok
male
volunt
written
inform
consent
arbidol
urin
sampl
collect
within
period
h
blank
urin
sampl
collect
prior
dose
urin
sampl
frozen
immedi
collect
none
subject
take
continu
medic
aliquot
urin
sampl
methanol
ad
mixtur
vortexmix
centrifug
g
min
supernat
transfer
glass
tube
evapor
dryness
stream
nitrogen
reconstitut
solut
methanol
ammonium
acet
vv
type
sigma
chemic
co
st
loui
mo
usa
use
hydrolysi
glucuronid
conjug
incub
perform
two
sampl
one
blank
urin
arbidol
urin
incub
aliquot
urin
mix
citrat
buffer
solut
ph
incub
carri
h
effect
glucuronidas
studi
compar
peak
intens
compound
interest
incub
compound
interest
includ
glucuronid
conjug
nonglucuronid
form
hydrolyz
form
studi
metabol
behavior
new
compound
one
first
step
fulli
understand
also
help
identifi
metabolit
origin
dealkyl
fragment
parent
compound
parent
compound
arbidol
produc
doublet
mz
ion
fig
presenc
br
molecul
structur
shown
fig
bromin
distinct
br
br
isotop
pattern
figur
show
spectra
ms
n
mz
ion
obtain
ion
trap
experi
ms
spectrum
mz
produc
ion
mz
fig
b
characterist
structur
arbidol
loss
dimethylamin
da
acetaldehyd
da
phenylthio
radic
da
sequenc
exist
fragment
ion
later
posit
confirm
exact
mass
measur
qtof
tabl
result
cid
pathway
arbidol
deduc
shown
fig
effect
identifi
metabolit
arbidol
possibl
metabol
pathway
well
possibl
metabolit
structur
first
theoret
propos
sole
base
arbidol
chemic
structur
fundament
metabol
rule
second
step
run
lcitm
fullscan
mode
blank
urin
arbidol
urin
four
inject
made
total
two
blank
arbidol
urin
incub
two
blank
arbidol
urin
incub
ms
spectra
obtain
four
sampl
compar
possibl
metabolit
could
identifi
import
pay
attent
insourc
decomposit
c
h
c
avoid
obtain
fals
posit
exist
br
br
isotop
pattern
also
help
identifi
compound
origin
arbidol
extract
ion
chromatogram
eic
detect
arbidol
metabolit
shown
fig
b
lcm
n
result
list
tabl
compar
experiment
identifi
metabolit
theoret
propos
help
increas
confid
find
propos
metabolit
analyz
lcitm
n
structur
elucid
metabolit
retent
time
ms
n
mass
spectra
compar
obtain
arbidol
basi
method
mention
parent
compound
arbidol
metabolit
identifi
sampl
human
urin
exist
phenol
hydroxyl
group
arbidol
expect
find
glucuronid
conjug
human
urin
confirm
exist
help
local
site
glucuron
use
treat
human
urin
glucuronid
conjug
hydrolyz
back
free
form
result
lc
peak
intens
glucuronid
conjug
expect
significantli
decreas
even
disappear
treatment
mean
time
lc
peak
intens
freeform
metabolit
relat
glucuronid
conjug
expect
increas
addit
use
contain
trace
activ
sulfatas
would
caus
sulfat
conjug
hydrolyz
procedur
result
treatment
content
glucuronid
sulfat
conjug
urin
sampl
decreas
glucuronid
conjug
decreas
much
greater
extent
sulfat
conjug
ms
n
spectra
arbidol
metabolit
studi
detail
structur
elucid
lc
retent
time
arbidol
standard
found
min
howev
peak
min
mz
also
observ
urin
sampl
experi
carri
later
show
peak
result
insourc
cid
arbidol
sulfat
conjug
critic
awar
exist
sulfat
conjug
well
relat
free
form
ion
insourc
cid
assign
new
metabolit
eic
mz
mz
da
fullscan
lcm
show
lc
peak
howev
lc
peak
mz
retent
time
min
observ
urin
sampl
treat
name
ms
mz
produc
ion
mz
loss
h
da
loss
methylamin
da
ms
spectrum
mz
mz
show
fragment
ion
mz
result
indic
demethyl
product
arbidol
demethyl
occur
dimethylamin
site
fact
mz
exist
prior
treatment
indic
demethylarbidol
exist
human
urin
glucuronid
conjug
form
free
form
basi
data
tent
identifi
methylaminomethyl
phenylthio
methyl
eic
mz
mz
c
da
fullscan
lcm
show
two
lc
peak
min
sampl
treat
intens
peak
increas
indic
intens
increas
result
hydrolysi
glucuronid
conjug
addit
peak
intens
decreas
littl
sequenc
cleavag
differ
arbidol
result
phenylthio
moieti
oxid
word
loss
phenylthio
moieti
da
first
step
fragment
molecul
uncommon
kind
fragment
sequenc
oddelectron
ion
form
first
follow
loss
radic
result
homolyt
bond
cleavag
neutral
group
lost
last
step
confirm
exist
fragment
ion
exact
mass
determin
qtof
ms
tabl
ion
mz
oddelectron
ion
indic
propos
mass
fragment
pattern
correct
fig
compar
synthet
refer
confirm
retent
time
min
identifi
dimethylamino
phenylsulfinyl
methyl
experi
later
confirm
peak
fragment
ion
sulfat
conjug
produc
insourc
cid
fact
observ
prior
lc
peak
intens
significantli
increas
also
indic
metabolit
exist
urin
free
form
well
glucuronid
conjug
form
eic
mz
mz
da
c
da
fullscan
lcm
show
two
lc
peak
min
sampl
treat
intens
peak
increas
twofold
indic
exist
glucuronid
conjug
peak
observ
treatment
indic
exist
free
form
glucuronid
conjug
human
urin
addit
peak
intens
decreas
littl
ms
n
spectra
show
similar
fragment
ion
ms
spectrum
mz
show
fragment
ion
mz
da
da
da
fragment
ion
form
lose
phenylsulfini
radic
da
phenylsulfini
radic
da
plu
one
neutral
methylamin
da
respect
suggest
plu
modif
occur
phenylthio
moieti
minu
modif
occur
dimethylamin
moieti
basi
data
tent
identifi
ethyl
phenylsulfinyl
methyl
experi
later
confirm
peak
fragment
ion
sulfat
conjug
produc
insourc
cid
eic
mz
mz
c
da
fullscan
lcm
show
singl
lc
peak
min
sampl
treat
addit
lc
peak
observ
min
mz
mean
exist
free
form
human
urin
ms
n
spectra
show
similar
fragment
ion
proton
molecul
mz
suggest
metabolit
dioxygen
deriv
arbidol
ms
mz
produc
product
although
phenylthio
moieti
dioxygen
fragment
sequenc
arbidol
compar
synthet
refer
identifi
dimethylamino
phenylsulfonyl
methyl
experi
later
confirm
peak
fragment
ion
sulfat
conjug
produc
insourc
cid
eic
mz
mz
da
c
da
fullscan
lcm
show
two
lc
peak
min
sampl
treat
intens
peak
increas
twofold
indic
free
form
glucuronid
conjug
exist
human
urin
addit
peak
intens
decreas
littl
characterist
fragment
ion
arbidol
lose
da
da
basi
data
tent
identifi
sulfat
glucuronid
conjug
arbidol
use
strategi
tent
identifi
sulfat
glucuronid
conjug
ndemethylarbidol
tent
identifi
sulfat
glucuronid
conjug
sulfonylarbidol
tent
identifi
sulfat
glucuronid
conjug
ndemethylsulfonylarbidol
sulfat
conjug
conspicu
insourc
decomposit
c
h
c
identifi
metabolit
show
fragment
ion
da
suggest
sulfat
conjug
sulfinylarbidol
ms
mz
mz
produc
fragment
ion
mz
also
result
lose
ch
sinc
phenylsulfinyl
moieti
form
new
chiral
center
two
diastereoisom
glucuronid
separ
chromatogram
therefor
might
identifi
two
metabolit
two
diastereoisom
glucuronid
conjug
use
strategi
tent
identifi
sulfat
glucuronid
conjug
basi
discuss
propos
major
metabol
pathway
arbidol
human
shown
fig
hplcitm
n
use
identif
arbidol
metabolit
human
urin
sampl
altogeth
metabolit
detect
identifi
major
metabolit
identifi
glucuronid
arbidol
glucuronid
sulfinyl
arbidol
msm
behavior
arbidol
identifi
metabolit
studi
detail
arbidol
metabolit
common
fragment
pattern
result
homolyt
bond
cleavag
cleavag
form
oddelectron
ion
loss
radic
arbidol
fragment
sequenc
first
lose
dimethylamin
da
follow
loss
acetaldehyd
da
phenylthio
radic
da
fragment
sequenc
also
observ
ndemethylarbidol
sulfonylarbidol
ndemethylsulfonylarbidol
howev
sulfinylarbidol
ndemethylsulfinylarbidol
fragment
sequenc
revers
phenylsulfini
radic
da
lost
first
follow
loss
dimethylamin
da
acetaldehyd
da
exact
mass
arbidol
sulfinylarbidol
fragment
ion
determin
qtof
ms
phase
ii
metabolit
sulfat
glucuronid
conjug
arbidol
ndemethylarbidol
sulfonylarbidol
ndemethylsulfonylarbidol
identifi
observ
neutral
loss
da
da
glucuron
acid
ms
spectra
sulfat
glucuronid
conjug
sulfinylarbidol
ndemethylsulfinylarbidol
unusu
fragment
pattern
phenylsulfinyl
radic
da
first
lost
c
h
c
loss
group
da
glucuron
acid
da
occur
da
loss
sinc
phenylsulfinyl
moieti
form
new
chiral
center
two
diastereoisom
separ
chromatogram
conclus
enough
identifi
phase
ii
metabolit
characterist
neutral
loss
ms
spectra
importantli
identif
metabolit
consid
factor
otherwis
highli
possibl
metabolit
identifi
fals
posit
good
exampl
insourc
fragment
ion
phase
ii
conjug
case
distinct
lc
peak
observ
